Loading...
Market
How will Biogen's stock change one week after EC's Leqembi decision?
2
Resolution / Starting Odds
Increase by more than 5% • 25%
Increase by 0% to 5% • 25%
Decrease by 0% to 5% • 25%
Decrease by more than 5% • 25%
Biogen stock price data from financial markets
Story
EMA Recommends Leqembi for Early Alzheimer's in Patients with ApoE4 Gene; Biogen Shares Rise 5%
Nov 14, 2024, 04:16 PM
The European Medicines Agency (EMA) has recommended the approval of Leqembi, a drug developed by Eisai and Biogen, for the treatment of early Alzheimer's disease. This decision comes after the agency initially rejected the treatment months prior. The recommendation was made by the Committee for Medicinal Products for Human Use (CHMP) and pertains specifically to patients with one or no copies of the ApoE4 gene. The drug has been shown to slow cognitive decline in these patients. Following the announcement, Biogen's shares rose by as much as 5%. The final verdict from the European Commission is still pending.
View original story
Similar markets
Increase by more than 5% • 25%
Decrease by more than 5% • 25%
Fluctuate within ±5% • 25%
No significant change • 25%
Increases by more than 10% • 25%
Increases by 5-10% • 25%
Changes by less than 5% • 25%
Decreases • 25%
Higher than competitors • 25%
On par with competitors • 25%
Lower than competitors • 25%
Significantly lower than competitors • 25%
Yes • 50%
No • 50%
File an appeal • 25%
Submit new data • 25%
Withdraw application • 25%
Other • 25%
Increase over 20% • 25%
Increase 0-20% • 25%
No change • 25%
Decrease • 25%
Increases by more than 10% • 25%
Decreases by more than 10% • 25%
Changes by less than 10% • 25%
No significant change • 25%
Stock rises by more than 10% • 25%
Stock rises by 0-10% • 25%
Stock falls by 0-10% • 25%
Stock falls by more than 10% • 25%
Increase > 10% • 25%
Increase 0-10% • 25%
Decrease 0-10% • 25%
Decrease > 10% • 25%
Increase by over 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by over 10% • 25%